Sachin Jain
Stock Analyst at Bank of America Securities
(2.98)
# 2,755
Out of 5,010 analysts
232
Total ratings
51.2%
Success rate
2.2%
Average return
Main Sectors:
Stocks Rated by Sachin Jain
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,500p | 12,428p | +32.76% | 88 | Sep 29, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 150.00 | CHF 120.92 | +24.05% | 30 | Sep 23, 2026 | |
| NVS Novartis AG | Reiterated: Buy | $169 → $181 | $145.71 | +24.29% | 6 | Sep 7, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €92.00 | €71.47 | +28.73% | 24 | Sep 4, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,350p | 1,856p | +26.62% | 16 | Sep 4, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €30.00 → €35.00 | €48.88 | -28.40% | 9 | Dec 2, 2025 | |
| BME: GRF Grifols, S.A. | Reiterated: Buy | €10.60 | €9.49 | +11.70% | 1 | Nov 25, 2025 | |
| GSK GSK plc | Reiterated: Sell | $48 → $23 | $49.35 | -53.96% | 4 | Oct 29, 2025 | |
| NVO Novo Nordisk | Reiterated: Hold | $138 → $57 | $38.31 | +48.86% | 37 | Oct 9, 2025 | |
| SWX: ROP Roche Holding AG | Upgraded: Buy | CHF 275.00 → CHF 340.00 | CHF 349.30 | n/a | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €205.00 | €137.40 | n/a | 3 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $49 | $35.57 | n/a | 4 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $25.65 | n/a | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $195 | $203.46 | n/a | 1 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $28.72 | n/a | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $177.12 | n/a | 1 | May 2, 2016 |
AstraZeneca PLC
Sep 29, 2026
Reiterated: Buy
Price Target: 16,500p
Current: 12,428p
Upside: +32.76%
Novartis AG
Sep 23, 2026
Reiterated: Buy
Price Target: CHF 150.00
Current: CHF 120.92
Upside: +24.05%
Novartis AG
Sep 7, 2026
Reiterated: Buy
Price Target: $169 → $181
Current: $145.71
Upside: +24.29%
Sanofi
Sep 4, 2026
Reiterated: Hold
Price Target: €92.00
Current: €71.47
Upside: +28.73%
GSK plc
Sep 4, 2026
Reiterated: Hold
Price Target: 2,350p
Current: 1,856p
Upside: +26.62%
Bayer Aktiengesellschaft
Dec 2, 2025
Reiterated: Buy
Price Target: €30.00 → €35.00
Current: €48.88
Upside: -28.40%
Grifols, S.A.
Nov 25, 2025
Reiterated: Buy
Price Target: €10.60
Current: €9.49
Upside: +11.70%
GSK plc
Oct 29, 2025
Reiterated: Sell
Price Target: $48 → $23
Current: $49.35
Upside: -53.96%
Novo Nordisk
Oct 9, 2025
Reiterated: Hold
Price Target: $138 → $57
Current: $38.31
Upside: +48.86%
Roche Holding AG
Sep 13, 2024
Upgraded: Buy
Price Target: CHF 275.00 → CHF 340.00
Current: CHF 349.30
Upside: n/a
Jun 12, 2023
Reiterated: Buy
Price Target: €110.00 → €205.00
Current: €137.40
Upside: n/a
May 11, 2023
Reiterated: Buy
Price Target: $48 → $49
Current: $35.57
Upside: n/a
Feb 2, 2023
Reiterated: Hold
Price Target: $24
Current: $25.65
Upside: n/a
Jan 17, 2023
Reiterated: Hold
Price Target: $195
Current: $203.46
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: $60
Current: $28.72
Upside: n/a
May 2, 2016
Reiterated: Buy
Price Target: n/a
Current: $177.12
Upside: n/a